Surgical outcomes of segmental bronchial sleeve resection in central non-small cell lung cancer

Rirong Qu, Wei Ping, Zhipeng Hao, Yixin Cai, Ni Zhang & Xiangning Fu

Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Keywords
Non-small cell lung cancer; segmental bronchial sleeve resection; pneumonectomy; sleeve lobectomy; outcome.

Correspondence
Xiangning Fu, Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Street 1095, Wuhan, 430030, Hubei Province, China.
Tel: +8613607150390
Fax: +86 027-83665211
Email: fxun2006@aliyun.com

Received: 12 February 2020; Accepted: 5 March 2020.
doi: 10.1111/1759-7714.13403
Thoracic Cancer 11 (2020) 1319–1325

Abstract
Background: The purpose of this study was to present the clinical and surgical results in patients who underwent segmental bronchial sleeve reconstruction.

Methods: The clinical and pathological data of 16 patients with central non-small cell lung cancer (NSCLC) who underwent segmental bronchial sleeve resection from April 2015 to May 2019 were retrospectively analyzed.

Results: According to the type of segmental bronchial reconstruction, procedures were divided into four types: right upper S6 sleeve lobectomy in three cases (type A); left lower lingular sleeve lobectomy in 10 cases (type B); left upper S6 sleeve lobectomy in two cases (type C); and left lower propriolateral superior sleeve lobectomy in one case (type D). A total of three patients (18.75%) experienced anastomotic complications, including two with anastomotic stenosis and one with anastomotic fistula. All patients achieved R0 resection. Apart from one patient who died of acute lung infection after surgery, the rest were successfully discharged. The average follow-up time was 28 months, and the overall survival rates of patients at one, two, and three years were 80.0%, 53.3%, and 40.0%, respectively.

Conclusions: Segmental bronchial sleeve resection is complex in technique and may have an increased risk of complications compared to a standard sleeve resection, but it is an effective and safe procedure, especially for selected patients with central lung cancer.

Introduction
At present, the incidence and mortality of lung cancer are first worldwide.1 The mortality rate of lung cancer in China ranks first among men and women, and the incidence rate ranks first among men, and second among women.2 For resectable lung cancer, the most effective method is still surgical resection and pneumonectomy, or sleeve bronchectomy is considered to be a safe and effective method for central lung cancer.3 In recent years, with the widespread application of bronchial sleeve resection, many studies4–8 have shown that compared with pneumonectomy, bronchial sleeve resection can preserve more lung parenchyma for patients, give a better quality of life, and significantly reduce the incidence of postoperative complications and mortality. There are nearly 30 types of bronchial sleeve reconstruction reported in the literature, but few reports of segmental bronchial sleeve resection. Herein, we collected retrospectively the clinical data of 16 patients undergoing segmental bronchial sleeve resection, and then focused on the procedure and its clinical outcomes.

Methods
Clinical data of patients
The clinical and pathological data of 16 patients with non-small cell lung cancer (NSCLC) who underwent segmental bronchial sleeve resection from April 2015 to May 2019 were retrospectively analyzed. There were 12 males and four females, with ages ranging from 48 to 68 years, and an average age of 60.21 ± 5.48 years. There were 11 patients with left lower lung tumor (68.8%), three patients with right upper lung tumor, and two patients with left upper lung tumor. There were two patients who underwent chemotherapy before surgery, six with underlying diseases before surgery, 10 with a history of smoking, three patients with a history of tumor...
disease, including two patients with a history of thyroid cancer, and one patient with a history of gastric cancer. This retrospective study was approved by the Ethics Committee of Huazhong University of Science and Technology, Tongji Medical College and patient consent was waived based on the nature of this study. Table 1 lists the baseline characteristics.

**Preoperative examination and evaluation methods**

All patients underwent routine blood, blood biochemical, and coagulation tests to evaluate their general hematological status prior to surgery, ECG (electrocardiogram), echocardiography, blood gas analysis, and pulmonary function assessment of patients’ surgical tolerance, and fiberoptic bronchoscopy to evaluate trachea and bronchial conditions. A chest enhanced computed tomography (CT) scan, head CT or MRI, neck ultrasound, abdominal ultrasound, and whole body bone scans were performed, and if necessary, a whole body PET-CT examination to assess distant metastasis. For patients where mediastinal lymph node metastasis was suspected prior to surgery, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was used.

**Operative technique**

All 16 operations were performed by the same surgeon. Irrespective of whether the procedure was a right or left thoracotomy, it was performed from the fifth intercostal posterolateral incision. Lymph nodes two, three, four, seven, eight, and nine for right thoracotomies, lymph nodes five, six, seven, eight, and nine for left thoracotomies, and noted lymph nodes 10, 11, 12, and 13 during thoracotomies on both sides were dissected for staging and a better exposure. After entering the thorax, the tumor invasion of the bronchi and surrounding large blood vessels was carefully evaluated, and freed according to standard lobectomy. First, the artery and vein of the lung lobe or segment were freed, then the artery, vein and lymph nodes around the bronchi were removed so that the bronchus was fully free of the target segment and main bronchus. When freeing the bronchus, we tried to avoid damaging the nutritional blood vessels around the bronchi to prevent poor healing of the anastomosis, and then the affected segment bronchus and part of the main bronchus was removed. The bronchial stump was sent for intraoperative frozen section analysis for pathology to confirm the bronchial margins were negative. In order to avoid the inconsistency between the size of the segmental bronchus and main bronchus, the segmental-bronchus was sutured continuously with a single layer of 5–0 proline after plastic surgery of the main bronchus. The anastomosis started from the posterior bronchial wall, and then the anterior wall was anastomosed with a 5–0 proline single-layer continuous suture. In order to avoid excessive anastomotic tension, in addition to fully freeing the bronchi and the main bronchus, the lower lung ligament was routinely fully freed and the pericardium opened around the pulmonary veins. After the anastomosis had been completed, intraoperative fiberoptic bronchoscopy was used to observe whether there was bleeding from the anastomosis and whether it had been effective. At the end of the suture, whether there was air leakage was checked by submerging the lung in saline solution and reventilating it under an airway pressure of 15 mmHg. If there was a leak, it could be successfully repaired. In order to further prevent anastomotic fistulas, our center is accustomed to using pedicled pericardial or thoracic surgical repair membrane to surround the anastomosis during left side

---

**Table 1 Clinical characteristics of patients**

| No. | Gender | Age, years | Tumor location | Smoking history | Comorbidity | Tumor history | Neoadjuvant treatment | Tumor size (cm) | cT stage | cTNM stage* |
|-----|--------|-----------|----------------|----------------|-------------|--------------|----------------------|----------------|----------|-------------|
| 1   | Female | 58        | RUL            | NO             | NO          | NO           | NO                   | 3.5            | N0       | IIA         |
| 2   | Male   | 52        | LLL            | YES            | NO          | NO           | NO                   | 4.0            | N2       | IIIA        |
| 3   | Male   | 53        | LLL            | YES            | Hypertension| NO           | NO                   | 5.2            | N0       | IIB         |
| 4   | Male   | 48        | LLL            | YES            | NO          | NO           | NO                   | 4.2            | N1       | IIB         |
| 5   | Female | 67        | LLL            | NO             | Diabetes    | YES          | NO                   | 3.8            | N1       | IIB         |
| 6   | Male   | 62        | LLL            | NO             | NO          | NO           | NO                   | 4.5            | N2       | IIIA        |
| 7   | Male   | 62        | LLL            | YES            | Hypertension| NO           | NO                   | 5.8            | N0       | IIB         |
| 8   | Female | 60        | LLL            | NO             | NO          | NO           | NO                   | 4.3            | N1       | IIB         |
| 9   | Male   | 61        | RUL            | YES            | Diabetes    | YES          | Chemotherapy         | 4.8            | N2       | IIIA        |
| 10  | Male   | 68        | LUL            | YES            | NO          | NO           | NO                   | 3.8            | N0       | IIA         |
| 11  | Male   | 65        | LUL            | NO             | Hypertension| NO           | NO                   | 3.5            | N1       | IIB         |
| 12  | Male   | 58        | LLL            | YES            | NO          | NO           | NO                   | 4.1            | N2       | IIIA        |
| 13  | Male   | 66        | LLL            | YES            | Hypertension| NO           | Chemotherapy         | 6.2            | N1       | IIIA        |
| 14  | Male   | 64        | LLL            | YES            | NO          | NO           | NO                   | 3.5            | N0       | IIA         |
| 15  | Female | 56        | RUL            | NO             | YES         | NO           | NO                   | 4.6            | N2       | IIIB        |
| 16  | Male   | 55        | LLL            | YES            | NO          | NO           | NO                   | 5.5            | N0       | IIB         |

LLL, left lower lobe; LUL, left upper lobe; RUL, right upper lobe. *The IASLC eighth edition of TNM classification.
Table 2 Perioperative and long-term results of patients

| No. | Operation time (minutes) | Intraoperative blood loss (mL) | Type | pTNM stage* | Postoperative complications | Postoperative hospital stay duration (days) | Adjuvant treatment | Recurrence status | Survival months | Cause of death |
|-----|--------------------------|--------------------------------|------|-------------|----------------------------|--------------------------------------------|-------------------|------------------|----------------|----------------|
| 1   | 215                      | 150                            | AD   | II B        | NO                         | 7                                          | Chemotherapy      | NO               | 44             | Alive          |
| 2   | 230                      | 100                            | SCC  | III A       | NO                         | 6                                          | Both              | Local            | 20             | Recurrence     |
| 3   | 220                      | 50                             | SCC  | II B        | NO                         | 10                                         | NO                | NO               | 38             | Alive          |
| 4   | 210                      | 100                            | AD   | II B        | NO                         | 8                                          | Radiotherapy      | NO               | 42             | Alive          |
| 5   | 200                      | 250                            | SCC  | III A       | Arrhythmia                 | 12                                         | Chemotherapy      | Distant          | 11             | Recurrence     |
| 6   | 320                      | 180                            | SCC  | III A       | NO                         | 7                                          | Both              | Local            | 34             | Alive          |
| 7   | 240                      | 40                             | SCC  | III A       | NO                         | 9                                          | Radiotherapy      | NO               | 37             | Heart disease   |
| 8   | 231                      | 100                            | SCC  | III A       | Arrhythmia                 | 11                                         | Chemotherapy      | Local            | 21             | Recurrence     |
| 9   | 245                      | 300                            | SCC  | III B       | Pneumonia                  | Death                                      | -                 | -                | -              | -              |
| 10  | 275                      | 280                            | AD   | II B        | NO                         | 6                                          | NO                | Local            | 34             | Alive          |
| 11  | 210                      | 150                            | SCC  | II B        | Stricture                  | 14                                         | Chemotherapy      | NO               | 43             | Pneumonia       |
| 12  | 190                      | 300                            | AD   | III A       | NO                         | 7                                          | Radiotherapy      | Local            | 18             | Recurrence     |
| 13  | 230                      | 400                            | SCC  | III A       | BPF                        | 24                                         | Chemotherapy      | Distant          | 11             | Recurrence     |
| 14  | 180                      | 50                             | SCC  | II B        | NO                         | 7                                          | Chemotherapy      | NO               | 40             | Alive          |
| 15  | 300                      | 200                            | AD   | II B        | Stricture                  | 9                                          | Both              | Distant          | 8              | Recurrence     |
| 16  | 246                      | 350                            | SCC  | III A       | Stricture                  | 10                                         | Chemotherapy      | Local            | 15             | Pneumonia       |

AD, adenocarcinoma; SCC, squamous cell carcinoma. *The IASLC eighth edition of TNM classification was used; BPF: bronchopleural fistula; Both: chemotherapy + radiotherapy.
surgery; on the right side, the anastomosis is wrapped with a pedic vein or a thoracic surgical repair membrane which is a kind of surgical repair material made from bovine pericardium.

Statistical analysis
Statistical analysis was performed using SPSS 23.0 software. Continuous variables were presented as mean values ± standard deviation, and categorical variables were presented as numbers and percentages. Comparison of clinical data between the two types of patients was performed using the X² test. Fisher’s exact probability test was used when n < 40. P-values < 0.05 were considered to indicate statistical significance.

Results

Perioperative results
Surgery was successful in all patients. The average operation time was 239.6 ± 38.6 minutes (180–320 minutes). The average intraoperative blood loss was 252.4 ± 101.8 mL (40–400 mL), and average postoperative hospital stay was 11.7 ± 5.8 days (6–24 days). A total of six patients (37.5%) had complications after operation, two had arrhythmia, one had pulmonary infection, two had anastomotic stenosis, and one had an anastomotic fistula. Apart from one patient who died as a result of acute lung infection after surgery, the rest of the patients improved after symptomatic supportive treatment and were discharged smoothly. The perioperative results are shown in Table 2.

Type of procedure and postoperative results
According to the different types of segmental bronchial reconstruction, procedures were divided into four types (Fig. 1): type A: right upper S6 sleeve lobectomy in three cases; type B: left lower lingular sleeve lobectomy in 10 cases; type C: left upper S6 sleeve lobectomy in two cases; type D: left lower propriolateral superior sleeve lobectomy in one case. Among the patients in type A, there was one case of a right upper lung

Figure 1 Four types of segmental bronchial reconstruction.
tumor which invaded the right upper lobe bronchus opening and the right lower dorsal pulmonary artery, and two cases of right upper lung tumor which directly invaded the right lower lung superior segment (S6). Among the patients in type B, there were five cases of left lower lung tumor which directly invaded the left tongue lobe (S4 + S5), three cases of left lower lung tumor which invaded the lower lobe bronchus opening and involved the left tongue lobe artery, and two cases of left lower lung tumor which invaded the left lingual bronchial root. In type C, there were two cases of left upper lung tumor which directly invaded the left lower lung superior segment (S6). Patients in type D had a left lower lung tumor with hilar lymph nodes invading the left propriolateral superior lobe artery. Postoperative stump was negative in all patients. Postoperative pathology: there were 11 cases of squamous cell carcinoma and five cases of adenocarcinoma. Postoperative pathological staging: there were six cases who were stage IIB, eight cases who were stage IIIA, and two cases who were stage IIIB. The type of procedure and postoperative pathological results are shown in Table 2.

**Postoperative recovery**

Comparing the pulmonary function and arterial blood gas examination results of the patients before and one month postoperatively, it was found that the patients’ FEV1, FEV1%, DLCO%, and PaO2 did not significantly decrease postoperatively, and the PaO2 and FEV1% indicators increased, but there was no significant increase. This shows that for patients with central lung cancer, segmental bronchial sleeve resection can largely preserve the lung parenchyma and improve the quality of life of patients. See Table 3 for details.

**Postoperative follow-up**

Patients who were discharged smoothly after surgery were followed up, either in the outpatient clinic or by telephone. Fiberoptic bronchoscopy, pulmonary function, and arterial blood gas analysis were reviewed one month after surgery to evaluate the anastomosis and postoperative pulmonary function recovery. Chest CT, tumor markers, and abdominal B-ultrasounds were reviewed every three months in the first year after surgery; the above indicators were reviewed every six months in the second year after surgery; the above indicators were reviewed annually thereafter. During the follow-up period, if the patient was determined to have lung symptoms, a bronchoscopy was performed together with other necessary procedures at any time. The follow-up time was calculated from the postoperative day and followed up to October 2019. The average follow-up time was 28 months (8–44 months). The overall survival rates of patients at one, two, and three years were 80.0%, 53.3%, and 40.0%, respectively. To date, six patients have survived.

### Discussion

Compared with lobectomy or sleeve lobectomy, patients with pneumonectomy had higher mortality and complications. During the 1980s and 1990s, the perioperative 30-day mortality rate for patients with pneumonectomy reported in the literature was approximately 6%–7%.5–11 In recent years, with the increasing number of pneumonectomy studies, foreign scholars have found that the mortality rate of pneumonectomy is about 4.6%–9.2%,4,7,12 but the mortality rates following lobectomy and sleeve lobectomy are 0.8% and 1.6%–2.0%, respectively.5,6 Therefore, for resectable non-small cell lung cancer (NSCLC), we should consider choosing sleeve lobectomy in order to avoid pneumonectomy.

However, the application of sleeve lobectomy is limited to the tumor invasion site and area. If the tumor involves multiple lobes or multilobed bronchus, simple sleeve lobectomy becomes difficult to complete. Therefore, expanded sleeve resection is warranted. A number of studies have reported13–15 that for locally advanced lung cancer, expanded sleeve resection is safe and feasible, and it can provide a better long-term prognosis compared with pneumonectomy. Segmental bronchial sleeve resection is a type of extended sleeve resection, but there are few reports on its feasibility and safety.16 In this study, for patients with tumors involving multiple lung lobes or multilobed bronchus, but not involving the segmental bronchus, we performed segmental main bronchial sleeve resection, and the postoperative mortality and complication rate did not increase compared with extended sleeve lobectomy.13,14 Extended sleeve lobectomy is an atypical bronchoplasty with resection of more than one lobe, which includes two lobe sleeve resection and single lobe or multiple lobes + single segment or multiple segments sleeve resection. All procedures in our study involved sleeve resection of the lung segment, and we called this procedure “segmental bronchial sleeve resection”.

Compared with sleeve lobectomy, extended sleeve lobectomy may increase the risk of postoperative complications. It has been previously reported15 that the incidence of postoperative pulmonary infection, postoperative delayed air leakage, and postoperative anastomotic fistula after extended sleeve

---

**Table 3** Comparison of pulmonary function and blood oxygen pre- and postoperatively

| Variables       | Preoperative | One month postoperative |
|-----------------|--------------|-------------------------|
| FEV1            | 2.5 ± 0.8    | 2.3 ± 0.7               |
| FEV1%           | 73.2 ± 9.3   | 75.8 ± 8.7              |
| DLCO%           | 82.6 ± 7.8   | 81.5 ± 8.2              |
| PaO2 (kPa)      | 10.2 ± 1.6   | 12.4 ± 1.8              |

DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in one second.
lobectomy were 14%, 13%, and 8%, respectively, and the total complication rate was 43%. In this study, the incidence of postoperative complications was 37.5%. Apart from one patient who died of postoperative acute lung infection, only one patient had an anastomotic fistula, two patients had arrhythmia, and two patients had an anastomosis, with no other complications. The reason is that good postoperative management is very important. A fiberoptic bronchoscopy is routinely performed at the end of the operation at our center in order to observe whether the anastomosis is bleeding and determine the condition of anastomosis. At the same time, the hemostasis and sputum at the distal end of the anastomosis can be sucked away. We determine whether fiberoptic bronchoscopy is needed according to a patient’s cough and sputum after surgery, as a small amount of sputum can cause anastomotic occlusion to form atelectasis, pneumonia, and even respiratory failure, because anastomotic edema is increased in the first two days after surgery.

For central lung cancer, the complete resection of the tumor is the guarantee of postoperative efficacy. Some researchers believe that the bronchial stump needs to be at least 1 cm away from the tumor to meet the requirements of expanded bronchial sleeve resection. In our procedure, we leave an approximately 12 mm tumor-free margin. More importantly, before deciding to perform an expanded bronchial sleeve resection, we should fully consider the patient’s quality of life, the risk of postoperative recurrence, and the occurrence of postoperative complications. Therefore, the preoperative evaluation of the patient is very important. In this study, the pulmonary function and arterial blood gas in patients were compared and analyzed before and after surgery, and we found that patients who tolerated segmental bronchial sleeve resection have good postoperative pulmonary function recovery, and subsequently a better quality of life. In terms of postoperative survival, the average follow-up time was 28 months (8–44 months), and the overall survival rates for patients one, two, and three were 80.0%, 53.3%, and 40.0% respectively. This result is similar to previous research. Therefore, segmental bronchial sleeve resection is safe and feasible in selected patients with central NSCLC.

In recent years, with the application of neoadjuvant therapy, particularly neoadjuvant immunotherapy, the survival rate of patients with unresectable NSCLC has improved. However, the benefit of this strategy in patients with resectable NSCLC remains unknown. Previous studies have shown that neoadjuvant therapy may cause hilar inflammation and fibrosis, which will increase surgical difficulties. For patients with resectable NSCLC who need sleeve resection, it may be better to perform surgical treatment followed by adjuvant treatment.

In conclusion, segmental bronchial sleeve resection expands the surgical indications for lung cancer, avoids pneumonectomy, and improves the quality of life of patients, especially for those with central NSCLC. Although its technology is more complicated, it is still a safe and feasible surgical procedure.

Disclosure
The authors report no conflicts of interest.

References
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (1): 7–34.
2 Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66 (2): 115–32.
3 Deslauriers J, Grégoire J, Jacques LF et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg 2004; 77 (4): 1152–6.
4 Park JS, Yang HC, Kim HK et al. Sleeve lobectomy as an alternative procedure to pneumonectomy for non-small cell lung cancer. J Thorac Oncol 2010; 5 (4): 517–20.
5 Ueda Y, Osada H, Osugi H. Thoracic and cardiovascular surgery in Japan during 2005. Gen Thorac Cardiovasc Surg 2007; 55 (5): 377–99.
6 Ueda Y, Fujii Y, Udagawa H. Thoracic and cardiovascular surgery in Japan during 2006. Gen Thorac Cardiovasc Surg 2008; 56 (7): 365–88.
7 Ludwig C, Stoeben E, Olszewski M, Hasse J. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma. Ann Thorac Surg 2005; 79 (3): 968–73.
8 Li Z, Chen W, Xia M et al. Sleeve lobectomy compared with pneumonectomy for operable centrally located non-small cell lung cancer: A meta-analysis. Transl Lung Cancer Res 2019; 8 (6): 775–86.
9 Ginsberg RJ, Hill LD, Eagan RT et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983; 86 (5): 654–8.
10 Deneffe G, Lacquet LM, Vermaut G. Surgical treatment of bronchogenic carcinoma: A retrospective study of 720 thoracotomies. Ann Thorac Surg 1988; 45 (4): 380–3.
11 Kadri MA, Dussek JE. Survival and prognosis following resection of primary non-small cell bronchogenic carcinoma. Eur J Cardiothorac Surg 1991; 5 (3): 132–6.
12 D’Amato TA, Ashrifi AS, Schuchert MJ et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 2009; 88 (4): 1079–85.
13 Hong TH, Cho JH, Shin S et al. Extended sleeve lobectomy for centrally located non-small-cell lung cancer: A 20-year singlecentre experience. Eur J Cardiothorac Surg 2018; 54 (1): 142–8.
14 Chida M, Minowa M, Miyoshi S, Kondo T. Extended sleeve lobectomy for locally advanced lung cancer. Ann Thorac Surg 2009; 87 (3): 900–5.
15 Hishida T, Aokage K, Yoshida J, Miyoshi T, Tsuboi M. Extended bronchopasty for locally advanced left lower lobe lung cancer: Surgical technique and outcomes. *Interact CardioVasc Thorac Surg* 2018; 27 (4): 602–5.

16 Berthet JP, Paradela M, Jimenez MJ, Molins L, Gómez-Caro A. Extended sleeve lobectomy: One more step toward avoiding pneumonectomy in centrally located lung cancer. *Ann Thorac Surg* 2013; 96 (6): 1988–97.

17 Okada M, Tsubota N, Yoshimura M *et al*. Extended sleeve lobectomy for lung cancer: The avoidance of pneumonectomy. *J Thorac Cardiovasc Surg* 1999; 118 (4): 710–3.

18 Li S, Chai H, Huang J, Zeng G, Shao W, He J. Hybrid video-assisted thoracic surgery with segmental-main bronchial sleeve resection for non-small cell lung cancer. *Surg Innov* 2014; 21 (2): 180–6.

19 Bott MJ, Yang SC, Park BJ *et al*. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2019; 158 (1): 269–76.

20 Krantz SB, Mitzman B, Lufti W *et al*. Neoadjuvant chemoradiation shows no survival advantage to chemotherapy alone in stage IIIA patients. *Ann Thorac Surg* 2018; 105 (4): 1008–16.

21 Bott MJ, Cools-Lartigue J, Tan KS *et al*. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. *Ann Thorac Surg* 2018; 106 (1): 178–83.